16 /100
LOW RISK
Score updated Jul 13, 2026

BEAM — Beam Therapeutics Inc. Dilution Risk Tracker

Track BEAM dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track BEAM — Get alerts when the score changes →

As of July 13, 2026, Beam Therapeutics Inc. (BEAM) has a DilutionWatch DilutionScore of 16/100, rated LOW dilution risk. Beam Therapeutics Inc. has a market capitalization of $3.39B, 102.88M shares outstanding, 254 institutional holders tracked. Key dilution vectors include approximately 33 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
22
💰 Cash Runway
10
📊 Float Risk
20
⚠️ Warrant Exposure
15
🔄Convertible Debt—

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for BEAM.
🔔 Track BEAM — Get forecast alerts →

💹 Market Data

Market Cap$3.39B
Shares Outstanding102.88M
Float87.97M
Cash$1.21B
Debt$100.19M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↓ 2.3% shares (2026Q1 vs prior)
254 institutional holders · 118.30M shares
#1 FMR LLC 12.45M shares
#2 ARK Investment Management LLC 12.13M shares
#3 FARALLON CAPITAL MANAGEMENT LLC 10.13M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest22.88M
Days to Cover8.4
% of Float26.0%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL CONVERTIBLE Dec 31, 2020
Full SEC filing analysis available with free account →

📰 Recent News

No recent news

📋 What This Means for BEAM Shareholders

Beam Therapeutics Inc. (BEAM) has a DilutionScore of 16/100, rated Low dilution risk. At this score level, DilutionWatch's real-time EDGAR monitoring shows limited near-term dilution signals. This does not mean zero dilution risk — shelf registrations can be filed and activated quickly — but the current filing profile shows no major outstanding dilution programs. Score as of July 13, 2026.

DilutionWatch's EDGAR monitoring for BEAM shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for BEAM in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for BEAM alongside comparable low-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track BEAM Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking BEAM — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — LOW Risk

Other LOW dilution risk stocks tracked by DilutionWatch with similar profiles:

LBTYA LBTYK AER AIG BABA

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for BEAM
📊 BEAM FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 BEAM Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.